At AAIC, Hints of Target Engagement for Some Drug Candidates
Early data suggests that CT1812 and AL001 shift biomarker levels in Alzheimer’s disease and frontotemporal dementia, respectively. BI 425809 fails to improve cognition.
NEWS
Umibecestat-Driven Cognitive Decline Is Reversible
Subtle memory deficits resolved after volunteers stopped taking the Novartis BACE inhibitor.
Seeing into the Human Synapse: New Tools Illuminate Alzheimer’s Hot Spot
New synaptic profiling and imaging techniques are enabling scientists to zero in on synaptic proteins, including phospho-tau, that make the difference between clinical Alzheimer’s and resilience.
FDA Accepts Aducanumab Application for Priority Review
The FDA will decide whether to approve the antibody as a treatment for Alzheimer’s disease on or before March 7, 2021.
Heart Health Is Brain Health, and It Starts in Your 20s
New research pushes back the age at which dementia risk from cardiovascular and metabolic factors begins. Should protective lifestyle interventions start in youth?
Can an Antibody Allele Boost Your Alzheimer’s Risk By Giving Herpes an Edge?
Homozygous carriers of GM17—a common IgG1 variant the HSV-1 virus has evolved to evade—had quadruple the risk of developing AD. In a small Swedish cohort, that is.
Lancet Commission’s Dementia Hit List Adds Alcohol, Pollution, TBI
In updating their broad evaluation of the risk literature, the commission blamed three more modifiable factors for causing 6 percent of all dementia, concluding that 40 percent of cases can be prevented.
IDEAS Finds Small Drop in Hospitalizations, Missing Goal
A slight drop in hospital admissions after amyloid PET, especially in people with positive scans, fell well short of the prespecified endpoint. Still, IDEAS is broadening into a research platform, and IDEAS 2 will add racial diversity.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Dash Genomics, Inc., Abcam, BrainXell, and the Jackson Laboratory.
SPOTLIGHT
For Young Adults, Too, Heart Health Is Brain Health
No age is too young to be aware of cardiovascular health affecting your brain. This was the alarming conclusion from several studies presented at the virtual AAIC last week. Scientists reported that hypertension, high cholesterol, obesity, and diabetes in people as young as 20 correlated with smaller brain volumes, worse cognition, and elevated dementia risk decades later. The findings imply that preventative interventions might have to start in young adulthood.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 5
- Total Items: 104
-
Jobs
- Total Items: 57
-
Conference Calendar
- New Items: 9
- Total Items: 72
- Member Directory
Latest Comments